Clinical trials: AAA
Alzheimer Disease
Fundus Camera Module for Early Detection of Alzheimer's Disease
Alzheimer's Disease (AD) affects tens of millions of people just in Europe. It is typically detected in its late stage when irreversible damage has already occurred, and current treatments are mostly conservative or palliative.
- Trial name
- NCT06841848
- Testing
- Fundoscopic Exam
- Where
- Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- I.R.C.C.S. Fondazione Santa Lucia
Insomnia
SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid
The objective of this study is to compare the efficacy of a sleep intervention on improving cognitive function in older adults with symptoms of insomnia, determine the association between change in sleep measures and change in…
- Trial name
- NCT03954210
- Testing
- Cognitive Behavioral Therapy for Insomnia (CBT-I), Sleep and Lifestyle Education
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Mild Cognitive Impairment, Dementia
Implications for Management of PET Amyloid Classification Technology
The main purpose of this study is to explore the impact of an amyloid positron emission tomography and computed tomography (PET/CT) scan on physician diagnosis and management, including drug management and care practices, for…
- Conditions
- Mild Cognitive Impairment, Dementia, Alzheimer's Disease
- Trial name
- IMPACT (NCT02778971)
- Testing
- [18F]Flutemetamol
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Utah
MCI, MCI Conversion to Dementia
Neurocognitive Assessment Platform 4 Alzheimer
The aging population in Europe is leading to an increase in neurodegenerative diseases, such as Alzheimer's disease (AD), which is expected to affect 152 million people worldwide by 2050.
- Conditions
- MCI, MCI Conversion to Dementia, AMCI - Amnestic Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NAP4A2020 (NCT07272811)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Frontotemporal Lobar Degeneration, Alzheimer Disease
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
The investigators will compare [18F]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched…
- Conditions
- Frontotemporal Lobar Degeneration, Alzheimer Disease, Cognitively Normal
- Trial name
- NCT05456503
- Testing
- [18F]-PI-2620
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Alzheimer's Disease
GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers
GSK2647544 is an orally available, selective inhibitor of Lp PLA2 that is being developed for the treatment of Alzheimer's disease.
- Trial name
- NCT01978327
- Testing
- GSK2647544, drug-drug interaction
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease, Healthy Volunteer
Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants
This study is designed to obtain basic information on three PET imaging tracers developed to detect tau pathology in the brain. In this study, healthy control participants and participants with AD will be studied.
- Trial name
- NCT02187627
- Testing
- [11C]RO6924963, [11C]RO6931643, [18F]RO6958948
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
PTSD, Alzheimer Disease
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: What is the safety of single ascending doses of the…
- Conditions
- PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease
- Trial name
- NCT05921929
- Testing
- Fluoroethylnormemantine (FENM)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- ReST Therapeutics
Alzheimer Disease, Dementia
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Disorders, Cognitive Decline
- Trial name
- ADKIT (NCT07294586)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease
Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly Subjects
To assess the safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of lecozotan SR in healthy young and elderly subjects.
- Trial name
- NCT00366483
- Testing
- Lecozotan SR
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Neuropsychological Tests, Memory
Adaptation and Normalization of a Verbal Episodic Memory Test in French Sign Language
To date, neuropsychological assessment of deaf signing persons is complicated by a lack of resources, especially the absence of tools available in French Sign Language (LSF).
- Conditions
- Neuropsychological Tests, Memory, Alzheimer Disease, Deafness
- Trial name
- RL-RI-LSF (NCT06902753)
- Testing
- Questionnaire and Physical Exam
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Poitiers University Hospital
Dementia, Memory Impairment
Cultural and Linguistic Adaptation and Normative Study of the Turkish Version of the Free and Cued Selective Reminding Test: 16-Word Version (FCSRT-T)
An Adaptation Study of Free and Cued Selective Reminding Test in Turkish
- Trial name
- FCSRT-T (NCT05756231)
- Testing
- SIHT-16
- Where
- Turkey (Türkiye)
- Volunteers
- 285 people, healthy volunteers welcome
- Sponsor
- Istanbul University
Alzheimer's Disease (AD), Neurodegenerative Disease
A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
The ADCHIP study (ST0067) is a non-interventional, monocentric, prospective study conducted by Amoneta Diagnostics and the Leenaards Memory Center (Lausanne, Switzerland).
- Conditions
- Alzheimer's Disease (AD), Neurodegenerative Disease, Dementia, Frontotemporal Dementia (FTD)
- Trial name
- ADCHIP (NCT07307872)
- Where
- Switzerland
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders
Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging
The MESO7 study is a prospective observational research project designed to investigate the mechanisms of resilience and neurodegeneration in neurological diseases and healthy aging.
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), Alzheimer Disease
- Trial name
- MESO7 (NCT07202494)
- Testing
- Imaging Techniques (MRI 3T & 7T, Functional, Structural, and Metabolic Imaging)
- Where
- France
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Dementia, Mental Health
Compass for Care: A Theory-driven Mobile Solution to Promote Well-being Among Caregivers of Individuals With ADRD
In the US, the over 11 million Americans currently providing unpaid care to a family member, relative, or friend with Alzheimer's disease or a related dementia (ADRD) are over 6 times more likely than the general population to…
- Trial name
- Compass4Care (NCT06249139)
- Testing
- Compass for Care (Well-being intervention), Compass for Care (Safety intervention)
- Where
- United States
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Pro-Change Behavior Systems
Alzheimer Disease, Dementia With Lewy Bodies (DLB)
Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder
This is a retrospective observational study to evaluate the clinical utility of blood-based biomarkers in the diagnosis and management of patients with a neurodegenerative disease (ND) or mental disorder (MD).
- Conditions
- Alzheimer Disease, Dementia With Lewy Bodies (DLB), Frontotemporal Dementia (FTD), Major Depressive Disorder (MDD)
- Trial name
- Synapsing-BK (NCT07314190)
- Where
- Spain
- Volunteers
- 1,799 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Cognitive Decline, Dementia
MIND Diet Intervention and Cognitive Decline
Phase III randomized controlled trial designed to test the effects of a 3-year intervention of the MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) on cognitive decline and brain neurodegeneration among 600…
- Conditions
- Cognitive Decline, Dementia, Alzheimer Disease, Vascular Dementia
- Trial name
- MIND (NCT02817074)
- Testing
- MIND Diet, Mild Weight Loss
- Where
- 2 sites in United States
- Volunteers
- 604 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Alzheimer's Disease
CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease
Alzheimer's disease (AD) is the most common cause of dementia and currently has no disease modifying treatments or simple accurate diagnostic tests.
- Trial name
- NCT02021682
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Neurodegenerative Diseases, Alzheimer's Disease
Functionalized Point of Care and 3D Printed Dental Aligners as Devices for Early Detection of Neurodegenerative Diseases
The treatment of dementias of neurodegenerative origin is currently limited to symptomatic drugs that are unable to interfere with the underlying mechanisms of neurodegeneration, as the pathological processes leading to dementia…
- Trial name
- PREDICTIVE (NCT07870070)
- Where
- Italy
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Alzheimer's Disease
An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption
This study will be a single-center, open-label, randomized, 3-treatment crossover study of single oral doses of an API-capsule formulation of E2609 under fasted conditions and a tablet formulation administered under fed and…
- Trial name
- NCT01716897
- Testing
- E2609
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.